Completed

Microarray Analysis for Human Genetic Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Urogenital Diseases+27

+ Genital Diseases

+ Adnexal Diseases

See all eligibility criteria
How is the trial designed

Observational
Study Start: June 1999
See protocol details

Summary

Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: July 2, 2017
Sourced from a government-validated database.Claim as a partner

Study start date: June 29, 1999

Actual date on which the first participant was enrolled.

The purpose of our study is to make use of a novel technology that the Cancer Genetics Branch of the NHGRI has been a leader in developing. This technology for genome-wide expression analysis, DNA microarray hybridization, is the focus of our protocol. We will access tissue banks collected by our collaborators that contain excess tissues obtained during routine clinical care. Specimens will be processed for large-scale gene expression analysis and DNA copy number determination using DNA microarrays. The development and analysis of this gene expression and gene copy number database are the primary purpose of this study. Currently available and new bioinformatics tools will be applied to the data for the characterization of disease subsets (e.g., early vs. advanced stage cancer) as well as to mine the data for specific genes which are linked to given disease states.

NCT00001898
Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: July 2, 2017
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

1500 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesAdnexal DiseasesBreast DiseasesEndocrine System DiseasesEndocrine Gland NeoplasmsFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGenital Neoplasms, FemaleGonadal DisordersCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueOvarian DiseasesSkin DiseasesSkin NeoplasmsUrogenital NeoplasmsSkin and Connective Tissue DiseasesNeuroectodermal TumorsNevi and MelanomasNeuroendocrine TumorsGenetic Diseases, InbornFemale Urogenital DiseasesBreast NeoplasmsMelanomaNeoplastic Syndromes, HereditaryOvarian Neoplasms

Criteria

Clinical inclusion/exclusion criteria will be dependent upon the collaborating Institutions' requirements.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 8 locations

Arizona Cancer Center

Tucson, United StatesOpen Arizona Cancer Center in Google Maps

Johns Hopkins University

Baltimore, United States

University of Michigan

Ann Arbor, United States

Memorial Sloan Kettering Cancer Center

New York, United States
Completed8 Study Centers